Effects of dosage titration of methylprednisolone acetate and triamcinolone acetonide on interleukin-1-conditioned equine articular cartilage explants in vitro.
Authors: Dechant J E, Baxter G M, Frisbie D D, Trotter G W, McIlwraith C W
Journal: Equine veterinary journal
Summary
# Editorial Summary Corticosteroid injections remain a cornerstone of intra-articular therapy for equine joint disease, yet their effects on cartilage metabolism remain incompletely understood. Dechant and colleagues used an in vitro model of inflamed cartilage explants (conditioned with interleukin-1) to compare how two commonly used corticosteroids—methylprednisolone acetate (MPA) and triamcinolone acetonide (TA)—affected glycosaminoglycan (GAG) synthesis and degradation at various dosages, hypothesising that lower doses would prove less harmful and that TA would outperform MPA. Unexpectedly, both drugs suppressed GAG synthesis regardless of dosage, with the highest MPA concentration (10 mg/ml) actually preserving synthesis better than lower doses; moreover, lower concentrations of both agents paradoxically increased GAG degradation compared to inflamed controls, whilst only the highest MPA dose reduced degradation, and neither drug restored metabolic markers to non-inflamed baseline levels. These counterintuitive findings—particularly that lower doses were not protective and that TA offered no advantage over MPA—diverge substantially from in vivo studies, raising questions about whether this cartilage explant model accurately reflects the clinical reality of intra-articular corticosteroid therapy and suggesting that practitioners should remain cautious about extrapolating dose-reduction strategies based purely on in vitro evidence.
Read the full abstract on PubMed
Practical Takeaways
- •In vitro findings suggest corticosteroid joint injections may not fully protect cartilage from inflammatory damage, challenging assumptions about protective efficacy and warranting careful clinical evaluation of their true benefit
- •Dosage reduction of corticosteroid intra-articular injections does not appear to reduce cartilage metabolic harm in this model, suggesting current clinical dosing practices may not be optimizable through simple dose reduction
- •Results diverge from in vivo studies, highlighting important limitations of in vitro cartilage models and emphasizing the need for continued clinical outcome research before changing current injection protocols
Key Findings
- •Both methylprednisolone acetate (MPA) and triamcinolone acetonide (TA) reduced glycosaminoglycan synthesis compared to control and IL-1 alone across all dosages tested
- •Highest MPA dosage (10 mg/ml) reduced GAG degradation whereas all TA dosages and lower MPA dosages increased GAG degradation compared to IL-1 alone
- •Neither corticosteroid counteracted the negative metabolic effects of IL-1 or maintained cartilage metabolism at control levels
- •Lower dosages of MPA and TA were not less detrimental to cartilage metabolism than higher dosages, contrary to the study hypothesis